



Derivation of an Outcome-Driven Threshold for Aortic Pulse Wave Velocity An Individual-Participant Meta-Analysis*

Running Title: Risk Threshold for Aortic Pulse Wave Velocity

De-Wei An, † Tine W. Hansen, † Lucas S. Aparicio, Babangida Chori, Qi-Fang Huang, Fang-Fei Wei,
Yi-Bang Cheng, Yu-Ling Yu, Chang-Sheng Sheng, Natasza Gilis-Malinowska, José Boggia,
Wiktorija Wojciechowska, Teemu J. Niiranen, Valérie Tikhonoff, Edoardo Casiglia, Krzysztof Narkiewicz,
Katarzyna Stolarz-Skrzypek, Kalina Kawecka-Jaszcz, Antti M. Jula, Wen-Yi Yang, Angela J. Woodiwiss,
Jan Filipovský, Ji-Guang Wang, Marek W. Rajzer, Peter Verhamme, Tim S. Nawrot,
Jan A. Staessen, ‡ Yan Li, ‡

The International Database of Central Arterial Properties for Risk Stratification Investigators§

Word Counts: Whole Manuscript 7894; Abstract 250;

Number: Tables 4; Figures 2; References 38

Correspondence:

Jan A. Staessen, MD, PhD,
3026-Alliance for the Promotion of Preventive
Medicine,
Leopoldstraat 59,
BE-2800 Mechelen, Belgium

Telephone: +32-15-41-1747
+32-47-632-4928 (cell)

Facsimile: +32-15-41-4542

Email: jan.staessen@appremed.org

Twitter: [jasta49](#)

1 * This article is dedicated to the memory of Prof Gavin R. Norton, MD, PhD, who passed away on 9
2 December 2022 shortly after having attended the IDCARS Consortium Meeting (Mechelen, Belgium,
3 1-3 December 2022) and whose comprehensive understanding of arterial physiology inspired all
4 authors of this paper.

5 † Joint first authors who contributed equally.

6 ‡ Joint senior and co-corresponding authors who contributed equally.

7 § The International Database of Central Arterial Properties for Risk Stratification Investigators are
8 listed in reference 21.

9 **Affiliations**

10 Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai
11 Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Centre for
12 Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
13 China (D.-W.A., Q.-F.H., Y. B.C., C. S.S., J. G.W., Y.L.); Non-Profit Research Association Alliance for
14 the Promotion of Preventive Medicine, Belgium (D.-W.A, T.W.H, B.C., Y.-L.Y., J.A.S.); Research Unit
15 Environment and Health, Department of Public Health and Primary Care, University of Leuven,
16 Leuven, Belgium (D.-W.A, Y.-L.Y., T.S.N.); The Steno Diabetes Center Copenhagen, Herlev, and
17 Center for Health, Capital Region of Denmark, Copenhagen, Denmark (T.W.H.); Servicio de Clínica
18 Médica, Sección Hipertensión Arterial, Hospital Italiano de Buenos Aires, Argentina (L.S.A.); Centre
19 for Environmental Sciences, Hasselt University, Hasselt, Belgium (B.C., T.S.N.); Department of
20 Internal Medicine, Faculty of Clinical Sciences, College of Health Sciences, University of Abuja, Abuja,
21 Nigeria (B.C.); Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University,
22 Guangzhou, China (F.-F.W.); Hypertension Unit, Department of Hypertension and Diabetology,
23 Medical University of Gdańsk, Poland (N.G.-M., K.N.); Centro de Nefrología and Departamento de
24 Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.); First
25 Department of Cardiology, Interventional Electrophysiology and Hypertension, Jagiellonian University
26 Medical College, Kraków, Poland (W.W., K.S.-S., M.R., K.K.-J); Department of Chronic Disease
27 Prevention, Finnish Institute for Health and Welfare, Turku, Finland (T.J.N., A.M.J.); Department of
28 Medicine, Turku University Hospital and University of Turku, Turku, Finland (T.J.N., A.M.J.);
29 Department of Medicine, University of Padova, Padova, Italy (V.T., E.C.); Department of Cardiology,
30 Shanghai General Hospital, Shanghai, China (W.-Y.Y.); School of Physiology, University of the
31 Witwatersrand, Johannesburg, South Africa (A.W.); Faculty of Medicine, Charles University, Pilsen,
32 Czech Republic (J.F.); Center for Molecular and Vascular Biology, KU Leuven Department of
33 Cardiovascular Sciences, University of Leuven, Leuven, Belgium (P.V.); Biomedical Science Group,
34 Faculty of Medicine, University of Leuven, Leuven, Belgium (J.A.S.).

35 **Correspondence:**

36 Prof Jan A. Staessen, Research Association Alliance for the Promotion of Preventive Medicine,
37 Leopoldstraat 59, BE-2800 Mechelen, Belgium.

38 Email: jan.staessen@appremed.org,

39 Prof Yan Li, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School
40 of Medicine, 192 Ruijin Er Road, Shanghai, 2000025, China. Email: liyanshcn@163.com

41

42 **ABSTRACT**

43 **BACKGROUND:** Aortic pulse wave velocity (PWV) predicts cardiovascular events (CVE)
44 and total mortality (TM), but previous studies proposing actionable PWV thresholds have
45 limited generalizability. This individual-participant meta-analysis is aimed at defining, testing
46 calibration, and validating an outcome-driven threshold for PWV, using two populations
47 studies, respectively, for derivation (IDCARS) and replication (MONICA).

48 **METHODS:** A risk-carrying PWV threshold for CVE and TM was defined by multivariable
49 Cox regression, using stepwise increasing PWV thresholds and by determining the threshold
50 yielding a 5-year risk equivalent with systolic blood pressure of 140 mmHg. The predictive
51 performance of the PWV threshold was assessed by computing the integrated discrimination
52 improvement (IDI) and the net reclassification improvement (NRI).

53 **RESULTS:** In well-calibrated models in IDCARS, the risk-carrying PWV thresholds
54 converged at 9 m/s (10 m/s considering the anatomical pulse wave travel distance). With full
55 adjustments applied, the threshold predicted CVE (HR [CI]: 1.68 [1.15-2.45]) and TM (1.61
56 [1.01-2.55]) in IDCARS and in MONICA (1.40 [1.09-1.79] and 1.55 [1.23-1.95]). In IDCARS
57 and MONICA, the predictive accuracy of the threshold for both endpoints was ~0.75. IDI
58 was significant for TM in IDCARS and for both TM and CVE in MONICA, whereas NRI was
59 not for any outcome.

60 **CONCLUSIONS:** PWV integrates multiple risk factors into a single variable and might
61 replace a large panel of traditional risk factors. Exceeding the outcome-driven PWV
62 threshold should motivate clinicians to stringent management of risk factors, in particular
63 hypertension, which over a person's lifetime causes stiffening of the elastic arteries as
64 waypoint to CVE and death.

- 65 **KEY WORDS:** aortic pulse wave velocity ■ arterial stiffness ■ cardiovascular risk ■ carotid-
- 66 femoral pulse wave velocity ■ mortality

67 **Nonstandard Abbreviations and Acronyms**

68	APPREMED	Non-Profit Research Association “ <i>Alliance for the Promotion of Preventive Medicine</i> ”
69		
70	BP	blood pressure
71	CI	95% confidence interval
72	CV	Cardiovascular
73	EPOGH	European Project on Genes in Hypertension
74	FLEMENGHO	Flemish Study on Environment Genes and Health Outcomes
75	HDL	high-density lipoprotein
76	HR	hazard ratio
77	IDCARS	International Database of Central Arterial Properties for Risk Stratification
78		
79	IDI	integrated discrimination improvement
80	IQR	interquartile range
81	MONICA	Monitoring of Trends and Determinants in Cardiovascular Disease Health Survey – Copenhagen
82		
83	MAP	Mean arterial pressure
84	NRI	net reclassification improvement
85	SPRINT	Systolic Blood Pressure Intervention Trial
86	PWV	aortic pulse wave velocity (carotid-femoral pulse wave velocity)
87		

88 INTRODUCTION

89 Over the human lifespan, aging and age-related risk factors, such as hypertension and
90 type-2 diabetes, lead to stiffening of the central elastic arteries. Consequently, the systolic
91 load on the arterial walls is cushioned less, a phenomenon further amplified by the early
92 return of reflected waves in late systole, while the tensile force maintaining a continuous
93 blood flow during diastole diminishes.¹ Aortic pulse wave velocity (PWV) is the gold
94 standard for the non-invasive assessment of central arterial stiffness² and predicts adverse
95 cardiovascular (CV) outcomes in a continuous manner.¹ However, in support of clinical
96 decision making European³ and Chinese⁴ guidelines proposed a fixed risk threshold of >12
97 m/s, which European experts subsequently lowered to >10 m/s, considering the difference
98 between the measured and anatomical pulse wave travel distance.^{2,5-7}

99 The literature supporting the guideline-endorsed PWV thresholds²⁻⁵ consists of patient⁸⁻¹⁵
100 and community-based¹⁶⁻¹⁹ studies with total or CV mortality or a composite CV endpoint as
101 outcome. In patients with end-stage kidney disease,^{9-12,15} metabolic syndrome,¹⁴
102 hypertension,⁸ or in patients undergoing transluminal aortic valve replacement,¹³ PWV risk
103 thresholds ranged from 10.5 m/s¹¹ to 11.8 m/s.¹² In Japanese-Americans,¹⁶ Japanese
104 men,²⁰ or middle-aged or elderly community-dwelling individuals,^{17,19} the PWV risk
105 thresholds ranged from 9.0 m/s¹⁸ to 13.7 m/s.¹⁹ In a cross-sectional meta-analysis of
106 16,867 individuals,⁷ the distribution of PWV was described as function of age in various
107 patient strata, including a subset of 1455 patients with optimal or normal blood pressure (BP)
108 considered to mirror population-based levels. Notwithstanding the merits of the previous
109 publications,^{11-14,16-19} PWV thresholds derived in patients with advanced disease¹¹⁻¹³ or
110 disturbed metabolic profile,¹⁴ in single-center population cohorts,¹⁶⁻¹⁹ in the elderly,¹⁷ or
111 based on the PWV distribution rather than adverse health outcomes⁷ cannot be
112 straightforwardly extrapolated to clinical practice. In view of these potential limitations, the

113 current individual-participant level meta-analysis, covering a wide age range, was
114 prospectively and specifically designed to define, test the calibration, and validate an
115 outcome-driven threshold for PWV, using the International Database of Central Arterial
116 Properties for Risk Stratification (IDCARS)²¹ as derivation dataset and the Copenhagen
117 subset of the Monitoring of Trends and Determinants in Cardiovascular Disease Study
118 (MONICA) for replication.²²

119 **METHODS**

120 **Data Availability**

121 All available data are shown within the article and the online-only Data Supplement.
122 Anonymized data are available from the corresponding author upon request, on condition
123 that an analysis plan is accompanying the request and that the principal investigators of all
124 cohorts approve data sharing.

125 **Study Cohorts**

126 The population studies included in the current meta-analysis met the principles outlined in
127 the Helsinki declaration for investigation of human participants.²³ The IDCARS study
128 protocols and the secondary analyses of anonymized data were approved by the competent
129 local Institutional or National Review Boards. Anonymized data from the Copenhagen
130 subset of the MONICA study were used for analysis. Participants gave written informed
131 consent at recruitment and renewed consent at each follow-up visit. The online only Data
132 Supplement provides full details on the selection of the study population and the methods
133 applied for collecting the clinical, biochemical and hemodynamic measurements and the
134 statistical analysis.

135 ***IDCARS — Derivation Cohort***

136 IDCARS cohorts qualified for inclusion in the present analysis, if peripheral and central BP
137 and CV risk factors had been measured at baseline, and if follow-up included both fatal and
138 nonfatal outcomes. Eight cohorts met these eligibility criteria (**Table S1**). Initial enrollment
139 took place from 1985 until 2015. For the present analysis, baseline refers to the first
140 measurement of central and peripheral BP along with CV risk factors (October 2000 until
141 February 2016). Across studies, the last follow-up took place from October 2012 to
142 December 2018 (**Table S1**). In the 8 qualifying IDCARS cohorts, 6546 individuals took part
143 in a re-examination including also the vascular examination. Of those, 2706 (41.3%) only
144 underwent a tonometric pulse wave analysis or had a substandard assessment of PWV. Of
145 the remaining 3840 participants, 462 (12.0%) were discarded, because they were younger
146 than 30 years, leaving 3378 IDCARS participants for statistical analysis.

147 ***MONICA — Replication Cohort***

148 In 1982-1984, a random sample of the residents of Glostrup County, one of the Western
149 suburbs of Copenhagen, Denmark was drawn with the goal to recruit an equal number of
150 women and men aged 30, 40, 50, and 60 years. In 1993-1994, the 3785 former participants
151 were invited for a follow-up examination at the Research Center for Prevention and Health in
152 Glostrup, of whom 2493 (65.9%) without history of CV disease between recruitment and
153 follow-up were examined.²² For the current analysis, 35 (1.40%) were excluded because of
154 inaccurate or missing PWV measurements, leaving 2458 participants for analysis.

155 **BP and PWV Measurement**

156 In IDCARS, brachial BP was the average of the first 2 consecutive readings. Mean arterial
157 pressure (MAP) was peripheral diastolic BP plus one-third of pulse pressure. In all IDCARS
158 cohorts included in the current analysis, PWV was measured by sequential
159 electrocardiographically gated recordings of the arterial pressure waveform at the carotid and

160 femoral arteries. The observers measured the distance from the suprasternal notch to the
161 carotid sampling site (distance A), and from the suprasternal notch to the femoral sampling
162 site (distance B). Pulse wave travel distance was calculated as distance B minus distance A.
163 ²¹ Pulse transit time was the average of 10 consecutive beats.²¹ PWV is the ratio of the
164 travel distance in meters to transit time in seconds. PWV measurements were discarded if
165 the standard error of the mean of 10 beats was more than 10%.²¹

166 In MONICA, a trained nurse obtained 2 consecutive BP readings with a random zero
167 mercury sphygmomanometer, which were averaged for analysis. Immediately thereafter, the
168 ~~same~~ trained nurse used 2 piezoelectric pressure transducers (Hellige GmbH, Freiburg im
169 Breisgau, Germany) to record the arterial wave simultaneously at the left common carotid
170 and femoral arteries. ²⁴ PWV was the travel distance between the 2 transducers, measured
171 on the body surface, divided by the transit time, determined manually by the foot-to-foot
172 velocity method.²⁴ For analysis, PWV measurements from 2 to 15 heart cycles were
173 averaged. The directly measured path length (MONICA) was converted to the subtracted
174 path length (IDCARS) in analyses involving both cohorts.^{7,25} For comparison of IDCARS
175 and MONICA data in normal participants with a published meta-analysis,⁷ path length was
176 converted to the path length considered to reflect the true anatomical distance, using
177 published formula.⁷ The biochemical methods are available in the online-only Data
178 Supplement (**p S5**).

179 **Ascertainment of Endpoint**

180 The co-primary endpoints in the current study were a composite CV endpoint, including CV
181 death and nonfatal CV events, and total mortality. The secondary endpoints included CV
182 mortality and fatal combined with nonfatal coronary events are defined in the Data

183 Supplement (pp **S5-S6**). In all outcome analyses, only the first event within each category
184 was considered. Participants free of events were censored at last follow-up.

185 **Statistical Analysis**

186 Statistical methods are described in detail in the online-only Data Supplement (pp **S6-S9**). In
187 exploratory analyses, incidence rates of endpoints were tabulated by tertiles of the PWV
188 distribution, while applying the direct method for standardizing rates in IDCARS for cohort,
189 sex and age (<40, 40-59, ≥60 years) and for sex and age group (40, 50, 60, and 70 years) in
190 MONICA. The cumulative incidence of the primary and secondary endpoints was plotted,
191 while accounting for cohort (in IDCARS only) and sex and age (IDCARS) or age group
192 (MONICA).

193 Multivariable-adjusted Cox models accounted for sex, age (IDCARS) or age group
194 (MONICA), MAP, heart rate, body mass index, the total-to-HDL serum cholesterol ratio,
195 smoking and drinking, use of antihypertensive drugs, history of diabetes mellitus,²⁶ and
196 previous CV disease (IDCARS only). Multivariable analyses involving IDCARS additionally
197 accounted for cohort. The proportional hazards assumption was checked by the
198 Kolmogorov-type supremum test. To compare relative risk across strata, deviation from
199 mean coding²⁷ was applied.

200 To determine an operational threshold for PWV, a two-pronged strategy^{28,29} was applied
201 using Cox regression in IDCARS. First, multivariable-adjusted HRs were computed for 0.1
202 m/s increments in PWV from the 10th to the 90th percentile of the PWV distribution. These
203 HRs expressed the risk in participants, whose PWV exceeded the cut-off point vs the
204 average risk in the whole population. The HRs with CIs were plotted as function of
205 increasing PWV thresholds to assess at which PWV level the lower 95% confidence limit of
206 the HRs crossed unity, signifying increased risk.²⁸ Next, PWV thresholds were obtained by

207 determining the PWV levels yielding a 5-year risk equivalent to the risk associated with an
208 office systolic BP of 120-, 130-, 140- and 160 mm Hg.²⁹ Model calibration was evaluated by
209 comparing the predicted risk against overoptimism-corrected Kaplan-Meier estimates in PWV
210 quintiles. The performance of PWV in risk stratification was assessed from 2-by-2 tables
211 providing specificity, sensitivity and related statistics, the area under the curve, and by the
212 integrated discrimination improvement (IDI) and the net reclassification improvement (NRI).³⁰
213 Finally, subgroup analyses were conducted in participants stratified by sex, age (<60 vs ≥60
214 years), and the approximate median systolic BP in IDCARS and MONICA (<130 vs ≥130
215 mm Hg).

216 **RESULTS**

217 **Baseline Characteristics**

218 In IDCARS, the number of interpolated values amounted to 108 (3.2%) for total serum
219 cholesterol, 198 (5.9%) for HDL cholesterol, 89 (2.6%) for blood glucose, 161 (4.8%) for
220 smoking and 723 (21.4%) for use of alcohol. In MONICA, the corresponding number of
221 interpolated values were 1 (0.04%), 1 (0.04%), 5 (0.20%), 0 (0%), and 49 (1.99%),
222 respectively.

223 The differences in the baseline characteristics between the IDCARS (2000-2016) and the
224 MONICA (1993-1994) participants at the time of the vascular examinations (**Table 1**) reflect
225 how lifestyle and treatment rates of hypertension changed over time, the ethnic make-up and
226 the age structure of the discovery and replication cohorts, and the high tax rates levels levied
227 on alcoholic beverages in Denmark. In both IDCARS and MONICA, women compared with
228 men had smaller body height, lower body weight and body mass index, lower systolic and
229 diastolic BP and MAP, and higher HDL cholesterol (**Table S2**). Across the IDCARS cohorts,

230 mean PWV (SD) ranged from 7.2 (1.5) m/s in the Polish Gdańsk cohort to 8.9 (2.4) m/s in the
231 participants recruited in Buenos Aires, Argentina (**Figure S1**). In the Copenhagen MONICA
232 cohort, PWV averaged 8.0 (2.5) m/s (**Figure S1**).

233 To assess concordance between the data resources used, normal individuals were
234 sampled from IDCARS and MONICA by excluding patients with a history of CV disease,
235 diabetes or treated hypertension and by discarding patients with dyslipidemia and smokers
236 (**Figure S2**). With standardization of the travel path applied, PWV by age group was largely
237 similar in IDCARS and MONICA (**Table S3**). Furthermore, in single regression, the main
238 correlates of PWV were age, systolic BP, pulse pressure and MAP (**Table S4**) with Pearson
239 correlation coefficients amounting to were 0.57, 0.45, 0.43 and 0.33 in IDCARS and to 0.55,
240 0.53, 0.48 and 0.47 in MONICA ($P < 0.001$ for all).

241 **Incidence of Endpoints**

242 Median follow-up of IDCARS participants amounted to 4.3 years (IQR: 3.8-6.9 years; 5th-
243 95th percentile interval: 2.1-11.6 years. Over follow-up (**Table S5**), 105 participants (3.11%)
244 died: 25 (0.74%) because of CV disease, 74 (2.19%) because of a non-CV illness (including
245 kidney failure), and 6 (0.18%) because of non-documented illnesses. The number of
246 IDCARS participants experiencing a major CV event or a coronary endpoint amounted to 155
247 (4.59%) and 77 (2.28%), respectively.

248 Median follow-up in MONICA was 12.6 years (IQR: 12.2-13.1 years; 5th to 95th percentile
249 interval: 3.5-13.4 years). Over this time period (**Table S5**), 393 (16.0%) died: 139 (5.66%)
250 because of CV disease and 254 (10.3%) because of a non-CV ailment. The number of
251 MONICA participants experiencing a major CV event, or a coronary endpoint amounted to
252 354 (14.4%) and 202 (8.22%), respectively. Across tertiles of the PWV distribution, in

253 IDCARS as well as in MONICA, the co-primary (**Table S6**) and secondary (**Table S7**)
254 endpoints steeply increased with higher PWV category ($P<0.001$).

255 **PWV Thresholds in IDCARS**

256 Multivariable-adjusted HRs were plotted against PWV thresholds stepwise increasing by
257 0.1-m/s over the 10th-90th percentile range of the PWV distribution (**Figure 1A** and **Figure**
258 **1B**). These multivariable-adjusted HRs expressed the 5-year risks of the co-primary
259 endpoints associated with successively increasing PWV thresholds compared to the average
260 risk in the whole IDCARS cohort. The lower limit of the 95% CI of the HRs crossed unity at a
261 PWV level of 8.7 m/s for the composite CV endpoint and at 8.8 m/s for total mortality. In
262 multivariable-adjusted Cox models (**Figure 1C** and **Figure 1D**), the PWV thresholds yielding
263 a risk equivalent with a systolic BP of 140 mm Hg were 8.5 m/s (CI: 7.5-9.6) for the
264 composite CV endpoint and 8.2 m/s (7.1-9.4) for total mortality. In all models PWV met the
265 proportional hazard assumption (test statistic ≤ 1.26 ; $P \geq 0.175$). In IDCARS, with adjustments
266 applied for cohort, sex, age and MAP, a PWV threshold of <9 m/s vs ≥ 9 m/s separated
267 (**Figure S3**) the cumulative incidence of the co-primary and secondary endpoints in a highly
268 significantly way ($P \leq 0.013$). The fully adjusted HRs associated with a PWV ≥ 9 m/s vs <9
269 m/s, were 1.68 (CI: 1.15-2.45) for the composite CV endpoint and 1.61 (1.01-2.55) for total
270 mortality (**Table 2**); for CV mortality and coronary endpoints (**Table S8**), the corresponding
271 HRs were 3.21 (1.06- 9.69) and 2.08 (1.21-3.59), respectively. In **Table 2** and **Table S8**, the
272 HRs associated with a 1-SD PWV increment were also presented allowing comparison with
273 the literature. The fully adjusted Cox models including the 9-m/s PWV threshold were well
274 calibrated as evidenced by similarity between the Kaplan-Meier estimates and the
275 multivariable-adjusted mean predicted risk for the CV endpoint ($P=0.654$) and total mortality
276 ($P=0.691$) across quintiles of observed and predicted risk (**Figure 1E** and **Figure 1F**). In

277 subgroup analyses stratified for sex, age or median systolic BP, none of the interactions
278 between the 9-m/s threshold and stratification groups reached significance (**Figure S4**).

279 **Replication in MONICA**

280 The MONICA data were interrogated to replicate the clinical relevance of the proposed 9-m/s
281 threshold. In line with the IDCARS findings, with adjustments applied for sex, age group and
282 MAP, a PWV threshold of <9 m/s vs \geq 9 m/s differentiated (**Figure S5**) the cumulative
283 incidence of the co-primary and secondary endpoints in a significant manner ($P \leq 0.001$),
284 except for coronary event ($P=0.145$). The fully adjusted HRs associated with a PWV \geq 9 m/s
285 vs <9 m/s, were 1.40 (1.09-1.79) for the CV endpoint and 1.55 (1.23-1.95) for total mortality
286 (**Table 2**); for CV mortality (**Table S8**) the HR was 1.53 (1.04-2.25), and for coronary events
287 it was not significant ($P=0.553$). In subgroup analyses stratified for sex, age or median
288 systolic BP, none of the interactions between the 9-m/s threshold and the stratification
289 groups reached significance (**Figure S4**).

290 **Predictive Performance**

291 In IDCARS, specificity, sensitivity and overall accuracy of the categorized PWV for the
292 prediction of the CV endpoint were 0.775, 0.607 and 0.769 and for the prediction of death
293 0.767, 0.571 and 0.764, respectively. Estimates in MONICA were of similar magnitude
294 (**Table 3**). In IDCARS, IDI for the 9-m/s PWV threshold amounted to 0.59% for the CV
295 endpoint ($P=0.020$) and to 0.28% ($P=0.198$) for total mortality, while in MONICA the
296 corresponding IDI values were 0.47 ($P=0.028$) and 0.85 ($P=0.002$), respectively (**Table 4**).
297 However, none of the NRI estimates in IDCARS or MONICA reached statistical significance
298 ($P \geq 0.108$).

299 **Rescaling of the PWV Threshold**

300 In the analysis of the IDCARS and Copenhagen MONICA data the pulse wave travel
301 distance was standardized to the subtraction method, as applied in IDCARS. To keep
302 consistency with current guidelines and the software presently implemented in devices for
303 PWV measurement, the 9-m/s threshold derived in IDCARS and replicated in MONICA was
304 rescaled to account for the difference between the measured and anatomical pulse wave
305 travel path. With this adjustment applied the 9-m/s threshold corresponded with 10 m/s
306 **(Figure 2)**.

307 **DISCUSSION**

308 In IDCARS a two-pronged approach was applied to determine outcome-driven PWV
309 thresholds in relation to the CV endpoint and total mortality. The PWV thresholds in well
310 calibrated models converged to 9 m/s, of which the prognostic value was replicated in
311 MONICA. The 2007 European Guideline for the Management of Hypertension³ proposed a
312 risk-carrying PWV threshold of 12 m/s, because this level was believed to represent a rough
313 estimate of high CV risk. The 2012 Consensus Document on the Measurement of PWV²
314 referred to the longitudinal patient and population studies published at that time to justify the
315 12-m/s threshold. However, the document² went on stating that the 12-m/s cut-off limit was
316 based on the direct measurement of the pulse transit distance. It therefore proposed a new
317 standard distance, i.e., (common carotid artery – common femoral artery) × 0.8).⁶ Applying
318 the new standard⁶ would result in a PWV threshold of 9.6 m/s, which was rounded to 10 m/s
319 as an easy to remember value for use in daily clinical practice.² In the current study, where
320 relevant, the directly measured travel distance (MONICA) was converted to the subtraction
321 distance (IDCARS)^{2,7} to increase comparability of the PWV estimates, either as descriptive
322 variable **(Figure S1)** or as exposure variable. Accounting for the anatomical pulse wave

323 travel distance showed that the 9-m/s threshold was equivalent with the 10-m/s cut-off, as
324 proposed in the European guidelines.^{3,7}

325 Several results presented in the current manuscript were generated as validation of the
326 data resources being used. First, the sex distribution of anthropometric and hemodynamic
327 characteristics and serum lipids was in line with the literature. In both IDCARS and MONICA,
328 women compared with men had smaller body height, lower body weight and body mass
329 index, lower systolic and diastolic BP and MAP, and higher HDL cholesterol (**Table S2**).
330 Second, the main correlates of PWV were age, systolic BP, pulse pressure and MAP (**Table**
331 **S4**). Third, to assess concordance with the literature, normal individuals were sampled from
332 the IDCARS and the MONICA cohorts, using the same exclusion criteria as described by
333 The Reference Values for Arterial Stiffness' Collaboration (**Figure S2**).⁷ With
334 standardization of the pulse wave travel path applied,^{2,7} PWV by age group was largely
335 similar in IDCARS and MONICA and in agreement with the normal subgroup in the
336 previously published cross-sectional meta-analysis (**Table S3**).

337 **Clinical Significance**

338 Modelling time-to-event using proportional hazard regression implies that the association
339 between adverse health outcomes and a risk factor is log-linear without a threshold at which
340 the risk suddenly increases. Population studies of office³¹ or out-of-office³² BP or serum
341 cholesterol³³ have unmistakably illustrated this concept. Given that in the present analysis,
342 the proportional hazard assumption for PWV was met, this construct is also applicable to
343 PWV. For this reason, throughout the current manuscript, the risk with PWV was not only
344 tabulated for the 9-m/s threshold, but also for a 1-SD increment in the continuously
345 distributed PWV. Notwithstanding the continuous associations between adverse health
346 outcomes and risk factors, operational or actionable thresholds of risk factors support

347 clinicians in risk stratification and in identifying the need to start pharmacological treatment.
348 Both in IDCARS and MONICA (**Table 3**), specificity of the 9-m/s threshold for the co-primary
349 endpoints was ~0.80, sensitivity was ~0.55, and the overall predictive accuracy close to 0.75.
350 IDI was significant for the CV endpoint in IDCARS and both co-primary endpoints in
351 MONICA, whereas NRI did not reach statistical significance. The multivariable-adjusted IDI
352 and NRI provide complementary information. Indeed, if addition of a marker to a model
353 including several risk factors increases the predicted probability of an endpoint, this is
354 reflected by a significant increase in IDI (**Table 4**). NRI indicates the extent to which a
355 biomarker improves diagnostic accuracy, which in the current analyses was not significant,
356 indicating that the discriminatory performance of PWV on top of commonly measured risk
357 factors, in particular sex, age, various BP indexes (**Table S4**) and dyslipidemia, is small. A
358 risk calculator is made available as **Data Supplement 2**. The SPARTE Investigators³⁴ and
359 the pathophysiology of aortic stiffness³⁵⁻³⁷ provide the interpretation of these findings. Aortic
360 stiffness, as captured by PWV, integrates the lifetime injury to the arterial wall. Elastin and
361 collagen are the major constituents of the extracellular matrix in the media of the central
362 elastic arteries. Elastin provides reversible extensibility during systole, while collagen
363 generates tensile strength. As people age, the elastin fibers become fragmented and the
364 mechanical load is transferred to collagen fibers, which are up to 1000 times stiffer than
365 elastin.³⁵ This process already starts in young adulthood, but the deposition of elastin by
366 vascular smooth muscle cells only occurs during fetal development and in early infancy, and
367 is switched-off thereafter.³⁶ This implies that elastin fiber damage is basically irreversible.³⁷
368 In the SPARTE Trial,³⁴ hypertensive patients were randomized to a therapeutic strategy
369 targeting the normalization of PWV, measured every 6 months (N=264) or to a therapeutic
370 strategy only implementing the European Hypertension Guidelines³ (N=272). After a median
371 follow-up of 48.3 months, there was no significant between-group difference in the primary

372 outcome, a composite CV endpoint (HR: 0.74; CI: 0.40-1.38). However, the secondary
373 endpoints were met by showing that PWV-driven treatment for hypertension reduces office
374 and ambulatory BP and aortic stiffening more than with application of BP-based guidelines.
375 In a subgroup of 337 participants enrolled in the Systolic Blood Pressure Intervention Trial
376 (SPRINT; 45% women; mean age: 64 years),³⁸ intensive treatment (target systolic BP <120
377 mm Hg) compared with usual treatment (<140 mm Hg) produced a mean between-group
378 reduction in systolic BP of 12.7 mm Hg (CI: 11.1-14.3 mm Hg) and at the end of the
379 18-month follow-up had attenuated the increase in PWV (9.0 vs 10 m/s; $P<0.001$). Basically,
380 both trials highlighted the pathophysiological concept, that age and high BP are the main
381 drivers of aortic stiffening. However, clinicians should be particularly concerned about
382 patients, in whom there is disparity between PWV, age and MAP, and retrace the previous
383 and current medical history of such patients to identify hidden risk factors. In the context of
384 the current study, a PWV risk threshold of 9 m/s (or 10 m/s with the correction for the
385 anatomical pulse wave travel path applied) should motivate clinicians to achieve stringent
386 control of BP, in particular systolic BP, the extending force to be buffered by the elastin
387 fibers.

388 **Limitations**

389 The current study should be carefully interpreted within the context of its limitations. First,
390 the diagnostic criteria and invasive management of coronary heart disease improved
391 drastically from the early 1990s to the current state of the art. In MONICA only a single case
392 of coronary revascularization was registered, whereas this number in IDCARS was 57 (**Table**
393 **S5**). These period effects might explain why the 9-m/s PWV threshold was not replicated for
394 coronary endpoints in MONICA, whereas PWV analyzed as continuously distributed variable
395 retained significance (**Table S8**). Second, as shown by the NRI, the incremental value

396 associated with PWV on top of all other risk factors was not significant (**Table 4**), explaining
397 why the NRI results were not graphically translated into an analysis of the area under the
398 curve of nested models. Finally, although IDCARS was a multi-ethnic cohort, Blacks were
399 not represented in the current data resource.

400 **Perspectives**

401 This individual-participants meta-analysis of longitudinal population studies with a composite
402 CV endpoint and total mortality as co-primary endpoints identified, validated and replicated
403 9 m/s as new outcome-driven threshold for aortic PWV. With correction for the anatomical
404 travel path, this cut-off corresponds with the 10-m/s threshold proposed in European
405 guidelines.^{3,7} In quantitative terms, these outcome-driven thresholds refine risk stratification
406 (IDI), albeit with a nonsignificant amount (NRI). In settings where PWV measurement can be
407 implemented, exceeding the actionable thresholds should motivate clinicians to stringent
408 management of modifiable CV risk factors, in particular systolic BP, which over a person's
409 lifetime leads to elastin fragmentation in the wall of the central arteries, thereby causing
410 major CV complication and premature mortality.

411 **ARTICLE INFORMATION**

412 **Sources of funding**

413 The Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen,
414 Belgium (www.appremed.org) received a nonbinding grant from OMRON Healthcare Co. Ltd., Kyoto,
415 Japan, which supports the scholarships of D.-W.A, B.C., and Y.-L.Y.

416 The grants which supported the cohort studies are listed by country.

417 *Argentina*: The Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;

418 *Belgium*: European Union (HEALTH-F7-305507 HOMAGE), European Research Council (Advanced

419 Researcher Grant 2011-294713-EPLORE and Proof-of-Concept Grant 713601-uPROPHET),

420 European Research Area Net for Cardiovascular Diseases (JTC2017-046-PROACT), and Research

421 Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium (G.0881.13);

422 *China*: The National Natural Science Foundation of China (grants 82270469, 82070432 and

423 82070435), the Ministry of Science and Technology (2018YFC1704902), Beijing, China, and by

424 Shanghai Municipal Health Commission (2022LJ022 and 2017BR025);

425 *Czech Republic*: European Union (grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550)

426 and Charles University Research program „Cooperatio – Cardiovascular Science“.

427 *Denmark*: 01-2-9-9A-22914 from the Danish Heart Foundation and R32-A2740 from the Lundbeck

428 Fonden.

429 *Finland*: Academy of Finland (grant 321351), Emil Aaltonen Foundation, the Paavo Nurmi Foundation,

430 the Urmas Pekkala Foundation, and the Hospital District of South-Western Finland;

431 *Italy*: European Union (grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550);

432 *Poland (Gdańsk)*: European Union (grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550);

433 *Poland (Kraków)*: European Union (grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550)

434 and Foundation for Polish Science.

435

436 **Disclosures**

437 None.

438

439 **Supplemental Material**

440 Expanded Methods

441 Tables S1-S8

442 Figure S1-S5

443

444 REFERENCES

- 445 1 Chirinos JA, Segers P, Hughes T, Townsend R. Large-artery stiffness in health and
446 disease: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019; 74:1237-1263.
- 447 2 Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T,
448 Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, et al. Expert consensus
449 document on the measurement of aortic stiffness in daily practice using carotid-femoral
450 pulse wave velocity. *J Hypertens*. 2012; 30:445-448.
- 451 3 Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty
452 AM, Kjeldsen SE, Laurent S, et al. 2007 ESH-ESC practice Guidelines for the
453 Management of Arterial Hypertension: ESH-ESC Task Force on the Management of
454 Arterial Hypertension. *J Hypertens*. 2007; 25:1751-1762.
- 455 4 Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and
456 treatment of hypertension — A report of the Revision Committee of Chinese Guidelines
457 for Prevention and Treatment of Hypertension. *J Geriatr Cardiol*. 2022; 16:182-241.
- 458 5 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL,
459 Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH guidelines for the
460 management of arterial hypertension. *Eur Heart J*. 2018; 39:3021-3104.
- 461 6 Huybrechts SAM, Devos DG, Vermeersch SJ, Mahieu D, Achten E, de Backer TLM,
462 Segers P, Van Bortel LM. Carotid to femoral pulse wave velocity: a comparison of real
463 travelled aortic path lengths determined by MRI and superficial measurements. *J*
464 *Hypertens*. 2011; 29:1577-1582.

- 465 7 The Reference Values for Arterial Stiffness' collaboration. Determinants of pulse wave
466 velocity in healthy people and the presence of cardiovascular risk factors: 'establishing
467 normal and reference values'. *Eur Heart J*. 2010; 31:2338-2350.
- 468 8 Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a
469 marker of cardiovascular risk in hypertensive patients. *Hypertension*. 1999; 33:1111-
470 1117.
- 471 9 London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave
472 reflections and survival in end-stage renal failure. *Hypertension*. 2001; 38:434-438.
- 473 10 Pannier B, Guérin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and
474 conduit arteries. Prognostic significance for end-stage renal disease patients.
475 *Hypertension*. 2005; 45:592-596.
- 476 11 Adragão T, Pires A, Birne R, Dias Curto J, Lucas C, Gonçalves M, Pita Negrão A. A plain
477 X-ray vascular calcification score is associated with arterial stiffness and mortality in
478 dialysis patients. *Nephrol Dial Transplant*. 2009; 24:997-1002.
- 479 12 Avramovski P, Janakievska P, Sotiroski K, Zafirova-Ivanovska B, Sikole A. Aortic pulse
480 wave velocity is a strong predictor of all-cause and cardiovascular mortality in chronic
481 dialysis patients. *Ren Fail*. 2013; 36:176-186.
- 482 13 Broyd CJ, Patel K, Pugliese F, Chebab O, Mathur A, Baumbach A, Ozkor M, Kennon S,
483 Mullen M. Pulse wave velocity can be accurately measured during transcatheter aortic
484 valve implantation and used for post-procedure risk stratification. *J Hypertens*. 2019;
485 37:1845-1852.

- 486 14 Ryliškyte L, Navickas R, Šerpytis P, Purnaite R, Zupkauskienė J, Juceviciene A,
487 Badariene J, Rimkiene MA, Ryliškiene K, Skiauteryte E, et al. Association of aortic
488 stiffness, carotid intima-media thickness and endothelial function with cardiovascular
489 events in metabolic syndrome subjects. *Blood Press*. 2019; 28:131-138.
- 490 15 Zhang Q, Yin K, Zhu M, Lin X, Fang Y, Lu J, Li Z, Ni Z. Combining pulse wave velocity
491 with galectin-3 to predict mortality and cerebrovascular and cardiovascular events in
492 hemodialysis patients. *Front Med*. 2020; 7:579021.
- 493 16 Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, Yamane K,
494 Kohno N. Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-
495 Los Angeles-Hiroshima study. *Circ J*. 2005; 69:259-264.
- 496 17 Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM,
497 Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S, et al. Elevated aortic pulse wave
498 velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning
499 older adults. *Circulation*. 2005; 111:3384-3390.
- 500 18 Inoue N, Maeda R, Kawakami H, Shokawa T, Yamamoto H, Ito C, Sasaki H. Aortic pulse
501 wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanese men.
502 *Circ J*. 2009; 73:549-553.
- 503 19 Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp
504 Pedersen C, Olsen MH. Thresholds for pulse wave velocity, urinary albumin creatinine
505 ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk
506 charts. *J Hypertens*. 2012; 30:1928-1936.

- 507 20 Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by
508 indices of vascular stiffness in elderly hypertensive patients. *Hypertens Res.* 2003;
509 26:609-614.
- 510 21 Aparicio LS, Huang QF, Melgarejo JD, Wei DM, Thijs L, We FF, Gilis-Malinowska N,
511 Sheng CS, Boggia J, Niiranen TJ, et al. The International Database of Central Arterial
512 Properties for Risk Stratification: research objectives and baseline characteristics of
513 participants. *Am J Hypertens.* 2021; 35:54-64.
- 514 22 Hansen TW, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen
515 J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the
516 general population. *Circulation.* 2006; 113:664-670.
- 517 23 World Medical Association. World Medical Association Declaration of Helsinki. Ethical
518 principles for medical research involving human subjects. *J Am Med Assoc.* 2013;
519 310:2191-2194.
- 520 24 Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI.
521 Assessment of arterial distensibility by automatic pulse wave velocity measurement.
522 Validation and clinical application studies. *Hypertension.* 1995; 26:485-490.
- 523 25 Vermeersch SJ, Rietzschel ER, De Buyere ML, Van Bortel LM, Gillebert TC, Verdonck
524 PR, Laurent S, Segers P, Boutouyrie P. Distance measurements for the assessment of
525 carotid to femoral pulse wave velocity. *J Hypertens.* 2009; 27:2377-2385.
- 526 26 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the
527 Expert Committee on the diagnosis and classification of diabetes mellitus. *Diabet Care.*
528 2003; 26 (Suppl. 1):S5-S20.

- 529 27 Hosmer DW, Jr., Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley &
530 Sons, 1989.
- 531 28 Gu YM, Thijs L, Li Y, Asayama K, Boggia J, Hansen TW, Liu YP, Ohkubo T, Björklund-
532 Bodegård K, Jeppesen J, et al. Outcome-driven thresholds for ambulatory pulse pressure
533 in 9938 participants recruited from 11 populations. *Hypertension*. 2014; 63:229-237.
- 534 29 Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart
535 T, Torp-Pedersen C, Lind L, Ibsen H, et al. Diagnostic thresholds for ambulatory blood
536 pressure monitoring based on 10-year cardiovascular risk. *Circulation*. 2007; 115:2145-
537 2152.
- 538 30 Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added
539 predictive ability of a new marker: from area under the ROC curve to reclassification and
540 beyond. *Stat Med*. 2008; 27:157-172.
- 541 31 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration.
542 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of
543 individual data for one million adults in 61 prospective studies. *Lancet*. 2002; 360:1903-
544 1913.
- 545 32 Li Y, Thijs L, Zhang ZY, Asayama K, Hansen TW, Boggia J, Björklund-Bodegård K, Yang
546 WY, Niiranen TJ, Ntineri A, et al. Opposing age-related trends in absolute and relative
547 risk of adverse health outcomes associated with out-of-office blood pressure.
548 *Hypertension*. 2019; 74:1333-1342.
- 549 33 Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and
550 stroke in the Asia Pacific region. *Intern J Epidemiol*. 2003; N32:563-572.

- 551 34 Laurent S, Chatellier G, Azizi M, Calvet D, Choukroun G, Danchin N, Delsart P, Girerd X,
552 Gosse P, Khettab H, et al. SPARTE Study: normalization of arterial stiffness and
553 cardiovascular events in patients with hypertension at medium to very high risk.
554 *Hypertension*. 2021; 78:983-995.
- 555 35 Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on
556 changing arterial compliance and left ventricular load in a northern Chinese urban
557 community. *Circulation*. 1983; 68:50-58.
- 558 36 Wagenseil J, Mecham RP. Vascular extracellular matrix and arterial mechanics. *Physiol*
559 *Rev*. 2009; 89:957-989.
- 560 37 Wagenseil J, Mecham RP. Elastin in large artery stiffness and hypertension. *J*
561 *Cardiovasc Trans Res*. 2012; 5:264-273.
- 562 38 Upadhya B, Pajewski NM, Rocco MV, Hundley WG, Aurigemma G, Hamilton CA, Bates
563 JT, He J, Chen J, Chonchol M, et al. Effect of intensive blood pressure control on aortic
564 stiffness in the SPRINT-HEART. *Hypertension*. 2021; 77:1571-1580.
565

566 **Novelty and Relevance**

567 **What is New?**

- 568 ● IDCARS (N=3378) and MONICA (N=2458) are large population studies assuring
569 generalizability.
- 570 ● In well-calibrated multivariable models, the risk-carrying PWV thresholds in IDCARS
571 converged to 9 m/s, of which the prognostic utility was replicated in MONICA.
- 572 ● The 9-m/s PWV refined risk stratification on top of classical risk factors, albeit to a minor
573 extent.
- 574 ● Corrected for the anatomical pulse wave travel distance the 9-m/s threshold is equivalent
575 to 10 m/s.

576 **What Are the Clinical Implications?**

- 577 ● Over a person's lifetime, hypertension leads to irreparable elastin fragmentation in the
578 wall of elastic arteries, thereby causing major CV complications and death.
- 579 ● PWV integrates all unmodifiable and modifiable risk factors in a single variable, so that its
580 measurement should be encouraged for risk stratification.
- 581 ● Exceeding the risk-carrying PWV threshold should motivate clinicians to stringent
582 management of risk factors, in particular hypertension.

583 **FIGURE LEGENDS**

584 **Figure 1** Threshold and Calibration of Pulse Wave Velocity in 3378 IDCARS participants.

585 Hazard ratios (HRs) express the risk at each PWV level relative to the average risk in the
586 whole study population for composite cardiovascular endpoint (**A**) and total mortality (**B**) with
587 PWV at 8.7 and 8.8 m/s signifying increased risk by crossing unity (dotted line). PWV levels
588 yielding equivalent 5-year risks compared with systolic blood pressure categories for
589 composite cardiovascular endpoint (**C**) and total mortality (**D**) with bars indicating 5-year risks
590 and point and line for PWV thresholds. PWV levels at 8.5 and 8.2 m/s indicate equivalent risk
591 as a systolic blood pressure of 140 mmHg. Model calibration for the composite
592 cardiovascular endpoint (**E**) and total mortality (**F**), showing the predicted risk against
593 overoptimism-corrected Kaplan-Meier estimates in PWV quintiles. All analyses were
594 multivariable adjusted for cohort, sex, age, mean arterial pressure (excluding **C** and **D**), heart
595 rate, the total-to-high-density lipoprotein serum cholesterol ratio, smoking and drinking, use
596 of antihypertensive drugs, diabetes, and history of cardiovascular disease.

597 **Figure 2** Rescaling the Outcome-Driven Pulse Wave Threshold for the Anatomical Pulse
598 Wave Travel Distance Path

599 In the analysis of the IDCARS and the Copenhagen MONICA data the pulse wave travel
600 distance was standardized to the subtraction method, as applied in IDCARS. To keep
601 consistency with current guidelines and clinical practice, the 9-m/s threshold derived in
602 IDCARS and replicated in MONICA was rescaled to account for the difference between the
603 measured and anatomical pulse wave travel path, using the formula published in references
604 **2** and **7**. With this adjustment applied the 9-m/s threshold corresponded with 10 m/s. The
605 gray line represents the line of identity.

606

607 **Table 1. Baseline Characteristics by Cohort**

Characteristic	IDCARS	MONICA	P-Value
Number in group	3378	2458	
Number with characteristic (%)			
Ethnicity			
Chinese	637 (18.9)	0 (0)	
White Europeans	1896 (56.1)	2458 (100)	<0.001
South Americans	845 (25)	0 (0)	
Women	1872 (55.4)	1241 (50.5)	<0.001
Hypertension	1782 (53.4)	902 (36.7)	<0.001
Treated hypertension	1221 (36.4)	203 (8.3)	<0.001
Diabetes mellitus	207 (6.1)	72 (2.9)	<0.001
History of cardiovascular disease	443 (13.2)	0 (0)	<0.001
Smokers	600 (18.7)	1319 (53.7)	<0.001
Drinkers	996 (37.5)	75 (3.1)	<0.001
Mean of characteristic (SD)			
Age, y	55.2 (14.1)	54.0 (10.6)	<0.001
Body weight, kg	71.8 (16.0)	74.7 (14.4)	<0.001
Body height, cm	165.3 (10.3)	169.5 (9.0)	<0.001
Body mass index, kg/m ²	26.1 (4.5)	25.9 (4.2)	0.17
Systolic blood pressure, mm Hg	131.4 (19.6)	129.0 (19.0)	0.001
Diastolic blood pressure, mm Hg	79.7 (10.7)	82.1 (10.6)	<0.001
Mean arterial pressure, mm Hg	96.9 (11.9)	97.7 (12.5)	0.014
Heart rate, beats per minute	68.5 (11.1)	65.9 (10.7)	<0.001
Serum total cholesterol, mmol/L	5.04 (1.00)	6.15 (1.11)	<0.001
Serum HDL cholesterol, mmol/L	1.49 (0.41)	1.45 (0.42)	0.001
Total-to-HDL cholesterol ratio	3.7 (4.2)	4.6 (1.5)	<0.001
Blood glucose, mmol/L	5.18 (0.98)	4.90 (1.08)	<0.001
Pulse wave velocity, m/s	7.95 (2.14)	8.01 (2.49)	0.29
Median follow-up (IQR), y	4.3 (3.8-6.9)	12.6 (12.2-13.1)	<0.001

608 Abbreviations: IDCARS, International Database of Central Arterial Properties for Risk Stratification; MONICA, Monitoring
609 of Trends and Determinants in Cardiovascular Disease Health Study – Copenhagen; HDL, high-density lipoprotein; IQR,
610 interquartile range.

611 Body mass index was weight in kilograms divided by height in meters squared. BP was the average of 2 consecutive
612 readings. Hypertension was a BP of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic or being on antihypertensive treatment.
613 Mean arterial pressure was diastolic BP plus one third of pulse pressure. Diabetes was a self-reported diagnosis, use of
614 antidiabetic drugs, fasting blood glucose of ≥ 7 mmol/L, random blood glucose of ≥ 11.1 mmol/L, or diabetes documented in
615 practice or hospital records. Smoking was the use of smoking materials on a daily basis. Drinking was an average alcohol
616 intake of ≥ 5 g/day.

617 Unit conversion factors: to convert cholesterol from mmol/L to mg/dL, multiply by 38.67; glucose from mmol/L to mg/dL,
618 multiply by 18.

619 **Table 2. Co-Primary Endpoints in Relation to PWV Per Threshold and Analyzed as Continuously Distributed Variable**

Cohort / Endpoint	Ne/Nr	Model 1		Model 2	
		HR (95% CI)	P-Value	HR (95% CI)	P-Value
IDCARS (discovery)					
Cardiovascular endpoint					
PWV ≥ 9 vs < 9 m/s	92/807 vs 63/2571	1.76 (1.21-2.56)	0.003	1.68 (1.15-2.45)	0.007
PWV (+1 SD)	155/3378	1.18 (1.03-1.36)	0.019	1.18 (1.02-1.36)	0.025
Total mortality					
PWV ≥ 9 vs < 9 m/s	57/807 vs 48/2571	1.75 (1.10-2.76)	0.017	1.61 (1.01-2.55)	0.045
PWV (+1 SD)	105/3378	1.36 (1.17-1.58)	<0.001	1.32 (1.13-1.55)	<0.001
MONICA (replication)					
Cardiovascular endpoint					
PWV ≥ 9 vs < 9 m/s	160/576 vs 194/1882	1.56 (1.23-1.98)	<0.001	1.40 (1.09-1.79)	0.008
PWV (+1 SD)	354/2458	1.27 (1.18-1.37)	<0.001	1.24 (1.14-1.34)	<0.001
Total mortality					
PWV ≥ 9 vs < 9 m/s	194/576 vs 199/1882	1.71 (1.37-2.13)	<0.001	1.55 (1.23-1.95)	<0.001
PWV (+1 SD)	393/2458	1.26 (1.17-1.35)	<0.001	1.22 (1.13-1.32)	<0.001

620 Ne/Nr indicates number of events/number of participants at risk. PWV in MONICA was standardized to the subtraction method used in IDCARS. Model 1
621 accounted for cohort (IDCARS only), sex, age (IDCARS) or age group (MONICA), and MAP. Model 2 additionally accounted for the total-to-HDL serum
622 cholesterol ratio, smoking and drinking, use of antihypertensive drugs, and history of CV disease (IDCARS only).

623

624

625 **Table 3. Discriminative Performance of Pulse Wave Velocity**

Outcome	IDCARS	MONICA
Composite Cardiovascular Endpoint		
Categorized PWV (≥ 9 vs < 9 m/s)		
N° events/at risk (%)	74/807 vs 48/2571	125/576 vs 142/1882
Specificity (95% confidence interval)	0.775 (0.760-0.789)	0.794 (0.777-0.811)
Sensitivity (95% confidence interval)	0.607 (0.514-0.694)	0.468 (0.407-0.530)
PLR (95% confidence interval)	2.694 (2.304-3.151)	2.274 (1.954-2.648)
NLR (95% confidence interval)	0.508 (0.407-0.633)	0.670 (0.597-0.751)
Accuracy	0.769 (0.754-0.783)	0.759 (0.741-0.776)
AUC (95% confidence interval)	0.691 (0.647-0.735)	0.631 (0.600-0.662)*
Continuously distributed PWV		
N° events/at risk (%)	122/3378	267/2458
AUC (95% confidence interval)	0.749 (0.705-0.793)	0.710 (0.679-0.742)
Total Mortality		
Categorized PWV (≥ 9 vs < 9 m/s)		
N° deaths/at risk (%)	36/807 vs 27/2571	136/576 vs 133/1882
Specificity (95% confidence interval)	0.767 (0.753-0.782)	0.799 (0.782-0.816)
Sensitivity (95% confidence interval)	0.571 (0.440-0.695)	0.506 (0.444-0.567)
PLR (95% confidence interval)	2.457 (1.967-3.070)	2.515 (2.176-2.907)
NLR (95% confidence interval)	0.558 (0.420-0.743)	0.619 (0.547-0.700)
Accuracy	0.764 (0.749-0.778)	0.767 (0.750-0.783)
AUC (95% confidence interval)	0.669 (0.607-0.731)	0.652 (0.621-0.683)
Continuously distributed PWV		
N° deaths/at risk (%)	63/3378	269/2458
AUC (95% confidence interval)	0.714 (0.648-0.779)	0.724 (0.693-0.756)

626 Calculations were performed for the 5-year risk in IDCARS and the 10-year risk in MONICA. PLR is the
627 positive likelihood ratio (true positive rate/false positive rate. NLR is the negative likelihood ratio (false
628 negative rate/true negative rate). Accuracy is the overall probability that an individual is correctly classified.
629 All estimates in this table were unadjusted for other risk factors.
630 Significance of the AUC difference between IDCARS and MONICA: * $P \leq 0.05$

631 **Table 4. Integrated Discrimination Improvement and Net Reclassification Improvement by Adding Pulse Wave Velocity Per**
 632 **Threshold and as Continuously Distributed Variable to the Base Model**

Cohort Endpoint PWV Marker	Integrated Discrimination Improvement			Net Reclassification Improvement		
	IDI (%)	95% CI (%)	P-value	NRI (%)	95% CI (%)	P-Value
IDCARS (discovery)						
Cardiovascular endpoint						
PWV ≥ 9 vs < 9 m/s	0.59	(0.01, 1.83)	0.020	8.83	(-2.39, 21.0)	0.139
Continuous	0.52	(0.01, 1.74)	0.020	2.45	(-17.5, 13.4)	0.772
Total mortality						
PWV ≥ 9 vs < 9 m/s	0.28	(-0.17, 1.19)	0.198	13.0	(-10.5, 25.3)	0.158
Continuous	0.90	(-0.09, 4.14)	0.079	10.5	(-7.38, 24.3)	0.317
MONICA (replication)						
Cardiovascular endpoint						
PWV ≥ 9 vs < 9 m/s	0.47	(0.02, 1.41)	0.028	4.85	(-6.84, 12.13)	0.238
Continuous	1.25	(0.32, 2.44)	0.004	3.42	(-4.29, 13.03)	0.232
Total mortality						
PWV ≥ 9 vs < 9 m/s	0.85	(0.19, 1.94)	0.002	6.94	(-2.51, 14.31)	0.108
Continuous	1.09	(0.30, 2.04)	0.006	0.02	(-5.98, 8.73)	0.707

633 Calculations were performed for the 5-year risk in IDCARS and the 10-year risk in MONICA. The base model included cohort (IDCARS only), sex,
 634 age (IDCARS) or age group (MONICA), mean arterial pressure, heart rate, body mass index, the total-to-HDL serum cholesterol ratio, smoking and
 635 drinking, diabetes and history of CV disease (IDCARS only). Pulse wave velocity (PWV) in MONICA was standardized to the subtraction method
 636 used in IDCARS. The integrated discrimination improvement (IDI) is the difference between the discrimination slopes of the base model and the
 637 base model extended by PWV. The discrimination slope is the difference in predicted probabilities (%) between participants without and with an
 638 endpoint. The net reclassification index (NRI) is the sum of the percentages of participants reclassified correctly in individuals without and with an
 639 endpoint (see Data Supplement pp **S8-S9**). IDI and NRI estimates are given with 95% CI.



